Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiority, controlled trial (FREEDOM)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510981-18-00

Acronym

APHP231089

Enrollment

334

Registered

2024-07-23

Start date

2024-12-12

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma Multiple myeloma (MM) is a B cell malignancy and is one of the most frequent primary neoplasms of the bone marrow

Brief summary

the ORR after six cycles of salvage therapy, defined as the proportion of subjects who achieve complete response (CR) or partial response (PR) according to the IMWG criteria, following salvage therapy.

Interventions

DRUGDEXAMETHASONE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
the ORR after six cycles of salvage therapy, defined as the proportion of subjects who achieve complete response (CR) or partial response (PR) according to the IMWG criteria, following salvage therapy.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026